Dose-to-target of etanercept treatment in patients with juvenile idiopathic arthritis in patients age 12 years and older.

• Conditions: etanercept, juvenile idiopathic arthritis, dose tapering, discontinuation

• Registration Number: NL-OMON20690
• Lead Sponsor: Jan van Breemen Instituut, Reade

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

• Diagnosis: JIA, types: polyarthritis (RF negative and RF positive), oligo-arthritis (persistant and extended), psoriasic and enthesitis related arthritis and undifferentiated arthritis (according to the ILAR criteria).

• Age 12 years or older.

Exclusion Criteria

• Planned reasons for treatment discontinuation.

• JIA, type: systemic arthritis.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To determine the proportion of patients with JIA maintaining Minimal Disease Activity after dose interval prolongation of etanercept.

Secondary Outcome Measures

Name	Time	Method
1. To study the cost-effectiveness of tapering down etanercept treatment;<br /><br>2. To investigate whether the lowest effective etanercept dose will reduce the risk of adverse events;<br /><br>3. To study the predictive value of serum etanercept trough levels and other patient related factors for successful down titration.<br>